WALTHAM, Mass., Aug. 6, 2010 (GLOBE NEWSWIRE) -- On-Q-ity, a next-generation oncology diagnostics company developing products to improve cancer therapy effectiveness, today announced that the company's president and CEO, Mara G. Aspinall, has been selected as one of PharmaVOICE magazine's "100 Most Inspiring People in the Life Sciences."
The PharmaVOICE 100 selectees were nominated by PharmaVOICE readers who identified highly qualified leaders as people with influence who make a substantial positive impact on those around them. Ms. Aspinall is included in the category of "Commanders and Chiefs," who are described as "leaders who are forging new paths, anticipating trends, and initiating innovative strategies all while guiding their companies through a shifting marketplace."
"I continue to be amazed by the individuals whom our readers have identified as the most inspiring, motivating and outstanding leaders in the life sciences industry," stated Taren Grom, editor-in-chief and cofounder of PharmaVOICE. "It is our extreme pleasure to once again be able to pay tribute to the men and women who are driving change, providing guidance and fostering relationships to position the industry in the best way possible to serve the ultimate stakeholders: patients."
PharmaVOICE characterizes Aspinall as a "force in oncology" and makes clear that "few people have better credentials to realize the goal of improving tools available to physicians to diagnose, and thus treat, cancer than Mara Aspinall."
"I am honored to have been selected as one of PharmaVOICE's "100 Most Inspiring People in the Life Sciences," said Mara Aspinall, president and CEO of On-Q-ity. "Being included in this group of outstanding life science leaders is both humbling and gratifying, and I thank PharmaVOICE and its readers for recognizing not only my, but On-Q-ity's commitment to develop a truly transformational technology platform that we hope will positively change the way that cancer patients are treated."
This is the sixth year of the PharmaVOICE 100 and it continues to be a "must-read" and one of the most anticipated publications of the year by its readers and the industry.
To read a synopsis of the article, click on: www.pharmavoice.com
About PharmaVOICE 100
Established six years ago by PharmaVOICE magazine, the PharmaVOICE 100 is an annual list of individuals recognized for their positive contributions to the life-sciences industry. The distinguished honorees are nominated by thousands of PharmaVOICE readers are diverse and represent a broad spectrum including pharmaceutical, biotechnology, contract research, clinical trial, research and development, patient education, patient recruitment, advertising, regulatory, technology and others.
About On-Q-ity
On-Q-ity is a next-generation diagnostics company transforming cancer treatment through non-invasive diagnostic monitoring. The company is developing innovative diagnostics to identify the unique characteristics of an individual's cancer, predict the response to therapy, monitor the efficacy of treatment and identify the cancer's recurrence. The company's circulating tumor cell and biomarker technologies originated from groundbreaking research at Massachusetts General Hospital and the Dana Farber Cancer Institute and MIT, respectively. Headquartered in Waltham, MA, On-Q-ity is funded by Atlas Venture, Bessemer Venture Partners, MDV-Mohr Davidow Ventures, Northgate Capital and Physic Ventures. For more information: www.On-Q-ity.com